Scroll Top
Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles
Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles

Home » Newsroom » Page 5

Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles
By Admin Roshan

19 Oct: Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …

Read more

Read More
By Admin Roshan

23 Sep: Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

Conference Dates: September 27th-30th BETHESDA, Md., Sept. 23, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused …

Read more

Read More
By Admin Roshan

17 Sep: Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

– Conference Dates: September 20th-23rd – BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology …

Read more

Read More
By Admin Roshan

09 Sep: Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …

Read more

Read More
By Admin Roshan

08 Sep: Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease

GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters — Study results demonstrate an increase in GCase protein levels with transport to …

Read more

Read More
By Admin Roshan

02 Sep: Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …

Read more

Read More
By Admin Roshan

11 Aug: Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology — Granted Two Patents for Compounds that Stabilize G-Case for Gaucher’s Disease and other Synucleinopathies …

Read more

Read More
By Admin Roshan

03 Aug: Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …

Read more

Read More
By Admin Roshan

10 Jun: Gain Therapeutics Announces Issuance Of Two New Pct Patents Covering Gba And Galc Modulator Compounds For Treatment Of Cns Disorders

Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — …

Read more

Read More
By Admin Roshan

27 May: Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference

BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …

Read more

Read More
By Admin Roshan

17 May: Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May

BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …

Read more

Read More
By Admin Roshan

10 May: Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results

Completed successful initial public offering and raised $46 million in gross proceeds — Appointed four new independent board of directors to strengthen leadership team — …

Read more

Read More
By Admin Roshan

03 May: Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress

Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of …

Read more

Read More
By Admin Roshan

27 Apr: Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference

BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and …

Read more

Read More
By Admin Roshan

22 Apr: Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress

Abstract highlighting Gain’s STAR candidate for Parkinson’s disease selected as one of the 10 Best Abstracts at the conference BETHESDA, Md., April 22, 2021 (GLOBE …

Read more

Read More
By Admin Roshan

20 Apr: Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals

Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets BETHESDA, Md., April 20, …

Read more

Read More
By Admin Roshan

25 Mar: Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares

BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of …

Read more

Read More
By Admin Roshan

18 Mar: Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock

BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of …

Read more

Read More
By Admin Roshan

10 Mar: Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering

BETHESDA, Md., March 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering …

Read more

Read More
By Admin Roshan

11 Feb: Gain Therapeutics Presents Positive Pre-Clinical Data Supportive of In Vitro Target Engagement for Gaucher Disease, GM1 Gangliosidosis and Morquio B Programs at the 17th Annual WORLDSymposium™

STAR candidates for the treatment of Gaucher Disease enhance GCase activity in a neuronal cell model and reduce toxic accumulation of GCase substrate STAR candidates …

Read more

Read More
By Admin Roshan

04 Feb: Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium

BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric …

Read more

Read More
By Admin Roshan

02 Feb: Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors

BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. …

Read more

Read More
By Admin Roshan

15 Dec: GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for Research in Biomedicine and Neurocentro

– Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx)™ technology for the treatment of rare genetic and neurodegenerative diseases – The collaborative agreement …

Read more

Read More
By Admin Roshan

30 Nov: Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s disease November 30, 2020 09:40 ET | …

Read more

Read More
By Admin Roshan

12 Oct: Gain Therapeutics to Present New Preclinical Data on Brain Penetrant Allosteric Regulators at the 14th Meeting of the European Working Group on Gaucher Disease

October 13, 2020 08:00 ET | Source: Gain Therapeutics BETHESDA, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused …

Read more

Read More
By Admin Roshan

09 Sep: Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program

Collaboration to Focus on Rare Genetic and Demyelinating Diseases, Including Lysosomal Storage Diseases September 10, 2020 08:00 ET | Source: Gain Therapeutics BETHESDA, Md., Sept. …

Read more

Read More
By Admin Roshan

20 Jul: Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors

September 12, 2019 02:30 AM Eastern Daylight Time LUGANO, Switzerland–(BUSINESS WIRE)–Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes …

Read more

Read More
By Admin Roshan

20 Jul: Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing

July 21, 2020 08:00 ET | Source: Gain Therapeutics Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare genetic and neurodegenerative diseases, …

Read more

Read More
By Admin Roshan

23 Jul: Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications

July 23, 2019 02:30 AM Eastern Daylight Time LUGANO, Switzerland & BELLINZONA, Switzerland & GARDANNE, France–(BUSINESS WIRE)–Gain Therapeutics SA, a biotechnology company discovering and developing …

Read more

Read More
By Admin Roshan

25 Feb: Gain Therapeutics SA Announces Award of Grant Support from Leading Parkinson’s Research Foundations to Advance Its Proprietary Non Competitive Molecular Chaperones for Parkinson’s Disease

February 26, 2019 02:30 AM Eastern Standard Time LUGANO, Switzerland & BARCELONA, Spain–(BUSINESS WIRE)–Gain Therapeutics SA (a biotechnology company discovering and developing novel therapeutics to …

Read more

Read More
1 … 4 5 6
About Us
  • Overview
  • Leadership Team
  • Board of Directors
  • Scientific Advisory Board
  • Partners
  • Careers
Science & Technology
  • Platform Technology
  • Science
  • Posters
  • Publications
INVESTORS & MEDIA
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Investor Resources
  • SEC Filings
  • Governance Documents
  • 2024 Gain Therapeutics, Inc.
Linkedin-in Twitter Youtube
  • ©2023 Gain Therapeutics, Inc.
  • Pipeline
  • Perspectives
  • Contact Us
  • Sign up
Linkedin-in Twitter Youtube
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles